GLYCOVAXYN
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections.
GLYCOVAXYN
Social Links:
Industry:
Biotechnology Manufacturing Pharmaceutical
Founded:
2004-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.glycovaxyn.com
Total Employee:
11+
Status:
Active
Contact:
+41447338585
Total Funding:
34.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Namecheap DNS Contabo
Similar Organizations
AM Technology
AM Technology designs and manufactures dynamically mixed continuous flow reactors.
Current Employees Featured
Investors List
Sofinnova Partners
Sofinnova Partners investment in Series B - GlycoVaxyn
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Series B - GlycoVaxyn
Index Ventures
Index Ventures investment in Series B - GlycoVaxyn
Sofinnova Partners
Sofinnova Partners investment in Series A - GlycoVaxyn
Index Ventures
Index Ventures investment in Series A - GlycoVaxyn
Sofinnova Partners
Sofinnova Partners investment in Seed Round - GlycoVaxyn
Index Ventures
Index Ventures investment in Seed Round - GlycoVaxyn
Official Site Inspections
http://www.glycovaxyn.com
- Host name: ip108.ip-94-23-80.eu
- IP address: 94.23.80.108
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "GlycoVaxyn"
GlycoVaxyn - Crunchbase Company Profile & Funding
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It …See details»
GlycoVaxyn AG | ETH Zurich - ETH Zürich
GlycoVaxyn and GSK launched a research collaboration in December 2012 at which point GSK also entered as minority shareholder. In February 2015 GSK acquired remaining shares of …See details»
GlycoVaxyn Company Profile 2024: Valuation, Investors
GlycoVaxyn General Information Description. Operator of a biotechnology company intended to prevent and treat bacterial infections. The company's technology enables the development …See details»
GSK strengthens early stage vaccine pipeline with acquisition of ...
Feb 11, 2015 With today’s transaction, GSK has now purchased all shares in GlycoVaxyn, valuing the company at US $212 million (approximately £139 million). GlycoVaxyn was …See details»
Glycovaxyn AG - LinkedIn
GlycoVaxyn is a private Swiss biotechnology company developing a broad portfolio of novel bioconjugate vaccines to prevent and treat common, severe bacterial infections using its …See details»
GlaxoSmithKline (GSK) Buys Vaccine-Maker GlycoVaxyn For $190 …
Feb 11, 2015 GlaxoSmithKline is acquiring Switzerland-based GlycoVaxyn, which specializes in manufacturing vaccines for bacterial infections, for $190 million in a deal announced this morning.See details»
Janssen enters R&D collaboration with vaccine leader, GlycoVaxyn
Jan 10, 2013 Janssen and GlycoVaxyn enter a three-year research and development collaboration to develop a multi-valent bacterial vaccine. Janssen Pharmaceuticals, a …See details»
GSK Acquires GlycoVaxyn for $190M - genengnews.com
Feb 11, 2015 GlycoVaxyn’s platform technology is designed to work by transforming the gene cluster responsible for the biosynthesis of the bacterial lipopolysaccharide, capsule …See details»
Janssen boosts vaccines pipeline with GlycoVaxyn deal
Jan 8, 2013 Janssen has agreed a deal with Swiss vaccines specialist GlycoVaxyn to research and develop a vaccine for multiple bacterial pathogens. Its early development will see …See details»
GlycoVaxyn AG Signs Exclusive License Agreement and Enters …
Jan 4, 2013 GlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, …See details»
Swiss startup LimmaTech licenses GSK vaccine, hires ex-CureVac …
Jul 20, 2023 The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015. ... according to the World Health …See details»
GSK Teams with GlycoVaxyn on New Bacterial Vaccines
Dec 19, 2012 The firms have separately been involved in the bacterial vaccine space for some time. In 2010, GlycoVaxyn and researchers at Harvard Medical School’s Brigham and …See details»
GlycoVaxyn announces the initiation of a Phase I clinical trial in ...
Jul 1, 2014 GlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, …See details»
GlycoVaxyn's research spin-out LimmaTech starts operations
Aug 28, 2015 Following the acquisition, GlycoVaxyn’s operational research business was transferred to a new company, LimmaTech Biologics. LimmaTech Biologics is not a …See details»
Progress towards a glycoconjugate vaccine against Group A …
Mar 28, 2023 The Group A Carbohydrate (GAC) is a defining feature of Group A Streptococcus (Strep A) or Streptococcus pyogenes. It is a conserved and simple polysaccharide, comprising …See details»
A Shigella flexneri 2a synthetic glycan-based vaccine induces a …
Mar 10, 2023 Report from the World Health Organization’s Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. Vaccine 34 , 2865–9 (2016).See details»
GlycoVaxyn and Brigham and Women’s Win $3.4M to Develop
May 4, 2010 GlycoVaxyn and researchers at Harvard Medical School’s Brigham and Women’s Hospital received $3.4 million in NIH funding to support preclinical development of a …See details»
Safety, immunogenicity, and preliminary clinical efficacy of a …
GlycoVaxyn, Janssen Vaccines. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent …See details»
An antibacterial vaccination strategy based on a glycoconjugate ...
2 GlycoVaxyn AG, Grabenstrasse 3, Schlieren 8952, Switzerland. PMID: 26892556 DOI: 10.1038/nchem.2432 Abstract Certain non-mammalian cell wall sugars are conserved across …See details»
Developing an Effective Glycan-Based Vaccine for Streptococcus …
Mar 7, 2022 Streptococcus pyogenes is a primary infective agent that causes approximately 700 million human infections each year, resulting in more than 500 000 deaths. Carbohydrate …See details»